Tekmira Legacy Drug Launched in US by Licensee Spectrum | GenomeWeb

Tekmira Pharmaceuticals this week announced that Spectrum Pharmaceuticals, which licensed Tekmira's non-RNAi cancer drug Marqibo earlier this year, has launched the product in the US.

The drug is a version of the approved chemotherapeutic vincristine formulated with Tekmira's liposome technology. It is a legacy product developed by Tekmira prior to its becoming a pure-play RNAi drug developer, and was later licensed to Talon Therapeutics. Talon was acquired by Spectrum in July.

Tekmira stands to receive royalties on sales of Marqibo.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.